NCT02780674 - A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

October 23, 2017

Study Completion Date

November 27, 2017

Conditions

Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc

Interventions

BIOLOGICAL

MEDI7734

Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.

BIOLOGICAL

Placebo

One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.

Trial Locations (7)

Research Site, Danbury

Research Site, Duncansville

Research Site, Jacksonville

Research Site, DeBary

Research Site, Miami Springs

Research Site, Birmingham

Research Site, Anniston